Tuulia Vallius, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms, Glandular and Epithelial | 3 | 2017 | 484 | 1.180 |
Why?
|
| Ovarian Neoplasms | 5 | 2019 | 4837 | 0.600 |
Why?
|
| CA-125 Antigen | 2 | 2017 | 286 | 0.540 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2018 | 2017 | 0.450 |
Why?
|
| Tumor Burden | 1 | 2018 | 1914 | 0.410 |
Why?
|
| Proteins | 2 | 2017 | 6101 | 0.370 |
Why?
|
| Neoadjuvant Therapy | 2 | 2018 | 2726 | 0.350 |
Why?
|
| Radiopharmaceuticals | 2 | 2017 | 2662 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 11493 | 0.210 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2020 | 3474 | 0.170 |
Why?
|
| Pyrimidinones | 1 | 2020 | 371 | 0.160 |
Why?
|
| Organoplatinum Compounds | 2 | 2018 | 408 | 0.150 |
Why?
|
| Cisplatin | 2 | 2020 | 1642 | 0.150 |
Why?
|
| Receptors, Progesterone | 1 | 2021 | 1097 | 0.140 |
Why?
|
| Receptors, Estrogen | 1 | 2021 | 2186 | 0.110 |
Why?
|
| Receptor, erbB-2 | 1 | 2021 | 2416 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 11007 | 0.100 |
Why?
|
| Positron-Emission Tomography | 2 | 2018 | 6274 | 0.090 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2014 | 450 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2020 | 1973 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2017 | 1485 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 5169 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2015 | 6461 | 0.070 |
Why?
|
| Prognosis | 2 | 2018 | 29050 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 57768 | 0.060 |
Why?
|
| Research Design | 1 | 2019 | 5987 | 0.060 |
Why?
|
| Melanoma | 1 | 2022 | 5475 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 20123 | 0.060 |
Why?
|
| Aged | 5 | 2020 | 163253 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 5670 | 0.050 |
Why?
|
| Female | 8 | 2021 | 380197 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2015 | 5102 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2017 | 7879 | 0.040 |
Why?
|
| Platinum | 1 | 2019 | 233 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2018 | 77426 | 0.040 |
Why?
|
| Ecosystem | 1 | 2022 | 474 | 0.040 |
Why?
|
| Humans | 10 | 2022 | 744220 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 19907 | 0.040 |
Why?
|
| Middle Aged | 4 | 2020 | 213367 | 0.040 |
Why?
|
| Mammals | 1 | 2022 | 1144 | 0.040 |
Why?
|
| Models, Theoretical | 2 | 2019 | 3591 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2018 | 53280 | 0.040 |
Why?
|
| Taxoids | 1 | 2019 | 665 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1039 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 13668 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 40559 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 20817 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2022 | 2969 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2018 | 1962 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 39045 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2020 | 2455 | 0.020 |
Why?
|
| Adult | 3 | 2020 | 214035 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 3461 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 6535 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 3584 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2014 | 63119 | 0.020 |
Why?
|
| Cytokines | 1 | 2022 | 7326 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2019 | 6196 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2022 | 8950 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 7908 | 0.010 |
Why?
|
| Apoptosis | 1 | 2019 | 9728 | 0.010 |
Why?
|
| Young Adult | 1 | 2020 | 56436 | 0.010 |
Why?
|
| Animals | 1 | 2022 | 168788 | 0.010 |
Why?
|